Preventing Ventilator-Associated Pneumonia

This chapter examines two key studies on ventilator-associated pneumonia (VAP) prevention in intensive care units, focusing on an inhaled amicasin trial and the Profivap study assessing ceftriaxone's effectiveness. It discusses antibiotic stewardship, challenges in implementing new strategies, and the significance of adhering to strict patient selection criteria. The chapter also evaluates the role of procalcitonin in managing antibiotic durations and highlights the complexities of clinical practice in the context of emerging research findings.